<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03097107</url>
  </required_header>
  <id_info>
    <org_study_id>SARO.15.001.05</org_study_id>
    <nct_id>NCT03097107</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL</brief_title>
  <official_title>Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zydus Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zydus Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of Saroglitazar Magnesium 1, 2, and 4 mg in patients with&#xD;
      fasting triglyceride ≥500 mg/dL and ≤1500 mg/dL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SARO.15.001.04 is a multicenter, prospective, randomized, double-blind, placebo-controlled,&#xD;
      parallel arm, 12-week study designed to evaluate the safety and efficacy of Saroglitazar&#xD;
      Magnesium 1, 2 and 4 mg in patients with fasting triglyceride ≥500 mg/dL and ≤1500 mg/dL.&#xD;
&#xD;
      A total 124 subjects will be enrolled in a ratio of 1:1:1:1 to receive either Saroglitazar&#xD;
      Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg, or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Management decision to suspend the study due to recruitment issues&#xD;
  </why_stopped>
  <start_date type="Actual">April 6, 2017</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in triglyceride cholesterol levels</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Percentage change in triglyceride cholesterol levels from baseline to Week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change in TG-C</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Percentage change from baseline to Week 4 and 8 in TG-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in lipid profile.</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Percentage change from baseline to 12 in lipid profile.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Saroglitazar magnesium 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saroglitazar magnesium 1 mg tablet orally once a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saroglitazar magnesium 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saroglitazar magnesium 2 mg tablet orally once a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saroglitazar magnesium 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saroglitazar magnesium 4 mg tablet orally once a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet orally once a day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saroglitazar Magnesium 1 mg</intervention_name>
    <description>Randomly assigned patients will receive saroglitazar magnesium 1 mg orally once each morning before breakfast for 12 weeks</description>
    <arm_group_label>Saroglitazar magnesium 1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saroglitazar Magnesium 2 mg</intervention_name>
    <description>Randomly assigned patients will receive saroglitazar magnesium 2 mg orally once each morning before breakfast for 12 weeks</description>
    <arm_group_label>Saroglitazar magnesium 2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saroglitazar Magnesium 4 mg</intervention_name>
    <description>Randomly assigned patients will receive saroglitazar magnesium 4 mg orally once each morning before breakfast for 12 weeks</description>
    <arm_group_label>Saroglitazar magnesium 4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Randomly assigned patients will receive placebo orally once each morning before breakfast for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults subjects (≥18 year) of either gender.&#xD;
&#xD;
          2. Average fasting TG-C ≥500 mg/dL and ≤1500 mg/dL (from Visits 2 and 2.1).&#xD;
&#xD;
          3. Able and willing to give written informed consent and comply with the requirements of&#xD;
             the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of pancreatitis within 6 months of the initial screening visit (Visit 1);&#xD;
             patients that have an episode of pancreatitis after Visit 1 but before randomization&#xD;
             will not be randomized.&#xD;
&#xD;
          2. Patients with any history of pancreatitis may not be on GLP-1 agonists, DPP-4&#xD;
             inhibitors or pramlintide, with their last dose no sooner than 3 months prior to Visit&#xD;
             1; use of these agents by this population is prohibited throughout the duration of the&#xD;
             trial and follow-up period. [Patients without a history of pancreatitis on these&#xD;
             agents must be on a stable dose as of 3 months prior to Visit 1.]&#xD;
&#xD;
          3. History of &gt;5% weight gain or weight loss or participation in weight gain/loss program&#xD;
             in past 3 months and not in the maintenance phase as of Visit 1.&#xD;
&#xD;
          4. Diabetic (as per ADA guideline) patients with HbA1c &gt;9.5 %.&#xD;
&#xD;
          5. Patients on prandial/rapid acting insulin, thiazolidinediones (TZDs) or glitazars in&#xD;
             the 3 months prior to Visit 1.&#xD;
&#xD;
          6. Patients on unstable doses of basal insulin (i.e., glargine, detemir, NPH) with&#xD;
             unstable defined as a greater than 20% fluctuation in daily dose within the past 3&#xD;
             months.&#xD;
&#xD;
          7. Patients on anti-obesity medications within 6 months of Visit 1 (orlistat, lorcaserin,&#xD;
             phentermine, naltrexone/bupropion etc.).&#xD;
&#xD;
          8. Patients on drugs that may promote weight loss (i.e., anti-epileptic agents such as&#xD;
             topiramate, zonisamide and the anti-depressant bupropion) may not be taken, unless the&#xD;
             dose is stable for 3 months and the indication for use is not weight loss.&#xD;
&#xD;
          9. Patients on prohibited nutraceutical supplements contained in Annexure 1 that are&#xD;
             unwilling to wash-out starting at Visit 1 (and abstain from use throughout the&#xD;
             duration of the study, including follow-up).&#xD;
&#xD;
         10. Patients with unexplained hematuria prior to or first noted during Visit 1.&#xD;
&#xD;
         11. Patients with anemia who are undergoing repletion of deficiencies (iron, folate, B12)&#xD;
             not in the maintenance phase as of Visit 1.&#xD;
&#xD;
         12. Patients on concomitant lipid-lowering medications and not willing to participate in&#xD;
             Lead-in/Run-in Phase (Please refer Lead-in/Run-in Phase).&#xD;
&#xD;
         13. Patients having heart failure of NYHA class (III-IV), unstable angina, acute&#xD;
             myocardial infarction, stroke, transient ischaemic attack, any coronary&#xD;
             revascularisation procedure and hospitalization for acute coronary syndrome and&#xD;
             discharge within 6 months prior to screening.&#xD;
&#xD;
         14. Patients with Left Ventricular dysfunction (Left Ventricular Ejection Fraction (LVEF)&#xD;
             &lt;40%, as measured through ECHO).&#xD;
&#xD;
         15. Uncontrolled hypertension (SBP &gt;160 and/or DBP&gt;100).&#xD;
&#xD;
         16. An uncontrolled thyroid disorder&#xD;
&#xD;
               -  Uncontrolled hyperthyroidism is defined as any history of hyperthyroidism that&#xD;
                  has either not been treated with either radioactive iodine (RAI) and/or surgery&#xD;
                  -or- that has been treated with RAI and/or surgery, but has required ongoing&#xD;
                  continuous or intermittent use of thyroid hormone synthesis inhibitors (i.e.,&#xD;
                  methimazole or proplythiouracil) within 6 months of Visit 1.&#xD;
&#xD;
               -  Uncontrolled hypothyroidism is defined as initiation of thyroid hormone&#xD;
                  replacement therapy or dose adjustment of replacement therapy within 3 months of&#xD;
                  Visit 1.&#xD;
&#xD;
         17. History of GI malabsorption or history of gastric bypass, banding, or diversional&#xD;
             bariatric surgery.&#xD;
&#xD;
         18. History of active liver disease or gall stones or hepatic dysfunction demonstrated by&#xD;
             AST and ALT ≥2 times of upper normal limit (UNL) or bilirubin ≥1.5 times UNL at Visit&#xD;
             1.&#xD;
&#xD;
         19. History of myopathies or evidence of active muscle diseases demonstrated by CPK ≥5&#xD;
             times UNL at Visit 1.&#xD;
&#xD;
         20. History of any other concurrent serious illness or malignancy (except successfully&#xD;
             treated basal and squamous cell carcinoma of the skin), within the past 5 years (e.g.&#xD;
             tuberculosis, HIV).&#xD;
&#xD;
         21. Positive HIV, hepatitis A (positivity of IgM), hepatitis B, or hepatitis C at Visit 1.&#xD;
&#xD;
         22. History of excessive consumption of alcoholic beverages (consumes &gt;2 alcoholic drinks&#xD;
             per day or &gt;14 alcoholic drinks per week, or engages in binge drinking). For the&#xD;
             remainder of the study, patients should agree to refrain from excessive alcohol&#xD;
             consumption (i.e., &gt;2 alcoholic beverages per day), to maintain their current dietary&#xD;
             regimen, and to not alter their normal activity routines. (Note: patients should not&#xD;
             drink alcohol for at least 24 hrs prior to any site visit).&#xD;
&#xD;
         23. History of known allergy, sensitivity or intolerance to the study drugs and their&#xD;
             formulation ingredients.&#xD;
&#xD;
         24. Renal dysfunction demonstrated by abnormal eGFR &lt;50 mL/min/1.73 m2.&#xD;
&#xD;
         25. History of clinically significant* systemic steroid therapy (intramuscular,&#xD;
             intravenous, intra-articular, or oral route) within 3 months of the Visit 1 or&#xD;
             anticipated requirement for systemic steroid therapy at Visit 1(however, topical,&#xD;
             ophthalmic and inhaled steroids are allowed).&#xD;
&#xD;
             * Clinically significant' (i.e., no more than 5 days of systemic steroids treatment&#xD;
             within 3 months of Visit 1)&#xD;
&#xD;
         26. NSAID use in excess of a reasonably prescribed dose and/or use in individuals with a&#xD;
             history of complications resulting from these agents.&#xD;
&#xD;
         27. Participation in any other clinical trial in the past 3 months in which&#xD;
             investigational product was taken and/or a medical device was utilized. Patients that&#xD;
             were screened but not randomized for another study must wait 30 days to participate in&#xD;
             Visit 1.&#xD;
&#xD;
         28. Pregnancy (including a positive urine and serum pregnancy test at Visit 1), lactation&#xD;
             or planned pregnancy/lactation during any time during the lead-in, study or follow-up&#xD;
             periods.&#xD;
&#xD;
         29. Patients on hormonal contraception or hormone replacement therapy containing estrogen&#xD;
             (progesterone based contraception and testosterone replacement therapy are permitted&#xD;
             granted that dosing is stable for at least 3 months prior to Visit 1).&#xD;
&#xD;
         30. Women of childbearing potential (WOCBP) and men, UNLESS using effective contraceptive&#xD;
             methods, such as an intra-uterine device or other mechanical contraception method with&#xD;
             condom or diaphragm and spermicide) throughout the study. For male patients,&#xD;
             contraception measures (condom and spermicide) must be taken during the study, either&#xD;
             by the male participant or his female partner. (Note: Enrolled females otherwise must&#xD;
             be surgically sterilize for at least the 6 months preceding Visit 1 or postmenopausal,&#xD;
             defined as 12 months with no menses without an alternative medical cause).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deven V Parmar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Zydus Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Affiliated Research Center, Inc.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Encompass Clinical Research</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Research Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventura Clinical Trials</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Springs Health Partners</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research - Bradenton</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research - Lakeland</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oviedo Medical Research, LLC</name>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <zip>32765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research - Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>River Birch Research Alliance LLC</name>
      <address>
        <city>Blue Ridge</city>
        <state>Georgia</state>
        <zip>30513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drug Studies America</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herman Clinical Research, LLC</name>
      <address>
        <city>Suwanee</city>
        <state>Georgia</state>
        <zip>30024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedar-Crosse Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centennial Medical Group</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <zip>21075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Medical Research</name>
      <address>
        <city>Oxon Hill</city>
        <state>Maryland</state>
        <zip>20745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercury Street Medical</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Einstein Clinical Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triad Clinical Trials LLC</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic and Atherosclerosis Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group, Ltd.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wells Institute for Health Awareness</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Clinical Research - Lyndhurst</name>
      <address>
        <city>Lyndhurst</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Awasty Research Network, LLC</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Clinical Research, LLC - Willoughby Hills</name>
      <address>
        <city>Willoughby Hills</city>
        <state>Ohio</state>
        <zip>44094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Research Group, Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Bristol, LLC</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research - Richmond, Inc</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 24, 2017</study_first_submitted>
  <study_first_submitted_qc>March 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2017</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertriglyceridemia</keyword>
  <keyword>dyslipidemia</keyword>
  <keyword>saroglitazar magnesium</keyword>
  <keyword>lipid disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>See above.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

